论文部分内容阅读
探讨临床应用银杏叶提取物EGB-761(达纳康)对新生儿缺氧缺血性脑病的防治作用。对重度窒息足月新生儿随机分成干预组和对照组各37例。两组除常规处理外,干预组给于口服达纳康15mg/(kg·d),2次/日,疗程4周。两组均于入院第1、第4天各抽血测定GMP-140和IF,1周后作头颅CT检查。结果:两组第1天GMP-140和IF值均无差异,而第4天比较,GMP-140和IF值干预组低于对照组,显示有显著性差异。临床应用达纳康后明显降低了血浆GMP-140的水平,间接反映体内血小板活化因子受到抑制,增加红细胞变形能力使血液粘滞度降低,从而阻断了缺氧缺血后的一系列生化连锁反应。
To investigate the prevention and treatment of ginkgo biloba extract EGB-761 (Danakang) on neonatal hypoxic-ischemic encephalopathy. Severe asphyxia full-term newborns were randomly divided into intervention group and control group of 37 cases. Except routine treatment, the intervention group was given oral Danakang 15mg / (kg · d) twice a day for 4 weeks. GMP-140 and IF were measured in each group on the first and the fourth day after admission, and CT was performed one week later. Results: There was no difference between the two groups on the first day of GMP-140 and the IF value, but on the fourth day, GMP-140 and IF value intervention group was lower than the control group, showing significant differences. Clinical application of danacone significantly decreased plasma levels of GMP-140, indirectly reflecting the inhibition of platelet activating factor in vivo, increasing the ability of erythrocyte degeneration to reduce blood viscosity, thus blocking a series of biochemical chain after hypoxia-ischemia reaction.